NOVATO, CA--(Marketwired - Mar 23, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company
focused on the discovery and development of novel mTOR inhibitors is pleased to announce that the Japanese Patent Office has
allowed a key patent for TAM-01, a novel mTOR modulator, targeting unmet need in systemic lupus erythematosus (SLE). The
patent, owned by the Buck Institute for Research on Aging and licensed exclusively to Mount Tam Biotechnologies, provides
composition of matter protection for Mount Tam's lead compound in Japan, complementing Mount Tam's strong intellectual property
position in the United States.
"This is another important step for Mount Tam, one that addresses significant opportunities in important global markets," said
Mount Tam CEO Richard Marshak.
About Mount Tam Biotechnologies, Inc.
Mount Tam Biotechnologies was established to develop, optimize and bring to market novel
pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where
there is significant unmet need. Mount Tam is focused on the discovery and development of novel mTOR inhibitors, with specific
emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. Mount Tam believes it has an industry
leadership position in developing therapeutic products which address aberrations in the mTOR pathway, and is confident that both
TAM-01 and TAM-03 are significantly differentiated from currently marketed rapalogs and have the potential to bring significant
benefits to patients.
Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive
licensing and collaboration agreement. The licensed assets are highly target-specific polyketides. Mount Tam is advancing
its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has largely completed non-GLP
pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing
follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors
have been shown to have the potential to address unmet need.
For more information visit www.MountTamBiotech.com
Forward-Looking Statements:
The information disclosed in this press release is made as of the date hereof and reflects Mount Tam's most current assessment of
its historical position and financial performance. Actual results may differ from those contained herein due to factors outside
of the control of Mount Tam. Additionally, this press release may contain certain forward-looking statements and information, as
defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
and is subject to the Safe Harbor created by those sections.
These forward-looking statements are not guarantees of future performance and are subject to uncertainties and
other factors that could cause actual results to differ materially from those expressed in the forward-looking statements
including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility,
and other factors Mount Tam identifies from time to time in its filings with the SEC. Forward-looking statements are identified
by wording such as "scheduled (future sense)", "intend(s)", "plan(s)", "expect(s)", "believe(s)", "will", "estimate(s)",
"anticipate(s)", "expect(s)", "may", "would", "could" or "should" or, in each case, the negative thereof, other variations
thereon, or comparable terminology that implies anticipated future performance, timing of an IND application, or the results of
any such application. Although Mount Tam believes that the assumptions on which these forward-looking statements are based
are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on
those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The
forward-looking statements contained in this release are made as of the date hereof, and Mount Tam disclaims any intention or
obligation to update the forward-looking statements for subsequent events.